重大治疗改变对美国退伍军人类风湿关节炎患者广泛疾病活动度临床应答的影响:一项观察性研究
该历史性队列分析评估了2006年至2017年间美国退伍军人事务部RA注册中患者就诊记录,探讨重大治疗改变(MTC)对广泛疾病活动度范围内临床应答(ACR20)的影响。全人群共1208例患者(6138次就诊),活动性疾病亚组383例(1109次就诊)。结果显示,MTC与ACR20应答可能性增加相关,全人群风险比范围为1.67至2.22,活动性疾病亚组为1.51至1.60。
要点
- MTC与全人群及活动性疾病亚组中ACR20应答风险增加相关。
- 全人群风险比范围为1.67至2.22,活动性疾病亚组为1.51至1.60。
- 即使病程长且既往多线治疗的患者,MTC仍与临床改善相关。
核心结论
- MTC与临床改善相关,即使在长期RA且接受过多线既往治疗的患者中也是如此。
研究设计与样本
- 历史性队列分析,评估2006年1月1日至2017年9月30日期间VA RA注册的患者就诊记录。
- 纳入标准为风湿科就诊且具有3种疾病活动度指标(DAS28、CDAI、RAPID3),随访 visit 在2-6个月后。
- 分析全人群(1208例患者,6138次就诊)和活动性疾病亚组(383例患者,1109次就诊,≥6个压痛关节且≥6个肿胀关节)。
主要发现
- 全人群中,MTC就诊与所有疾病活动度指标下ACR20应答可能性增加相关。
- 全人群MTC vs 无MTC的ACR20总体风险比范围为1.67至2.22(跨疾病活动度指标)。
- 活动性疾病亚组中,MTC vs 无MTC的ACR20风险比范围为1.51至1.60。
关键数值与推荐
- 临床结局基于ACR20标准。
- 活动性疾病定义为≥6个压痛关节且≥6个肿胀关节。
- 全人群MTC vs 无MTC的ACR20风险比范围为1.67至2.22,活动性疾病亚组为1.51至1.60。
临床怎么用
- 对于已确诊且活动的RA患者,即使既往多线治疗,治疗调整仍可能带来临床改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the impact of major therapeutic change (MTC) on clinical response across a broad range of disease activity in US veterans with rheumatoid arthritis (RA). METHODS: This historical cohort analysis evaluated patient visits from the Veterans Affairs RA registry between January 1, 2006 and September 30, 2017. Eligible patient visits were a rheumatology visit with 3 disease activity measures, including the Disease Activity Score in 28 joints, the Clinical Disease Activity Index, and the Routine Assessment of Patient Index Data 3; the follow-up visit for all 3 disease activity measures was 2-6 months later. The full population and a subset of patients with active disease (≥6 tender joints, ≥6 swollen joints) were evaluated. Clinical outcome was based on the American College of Rheumatology criteria for 20% improvement in disease activity (ACR20). The effect of MTC on ACR20 response was presented as crude descriptive statistics and evaluated using standardized regression for population- and disease activity-level conditional effects. RESULTS: The full population comprised 1,208 patients (6,138 visits) and the active disease subpopulation included 383 patients (1,109 visits). Overall, visits with MTC were associated with increased likelihood of ACR20 response across all disease activity measures for the full population. Risk ratios for overall risk of ACR20 response for visits with MTC versus those without MTC ranged from 1.67 to 2.22 across disease activity measures among the full population and from 1.51 to 1.60 for the subpopulation with active disease. CONCLUSION: MTC was associated with clinical improvement, even among patients with longstanding RA who had received multiple prior therapies, which emphasizes the utility of therapy modifications for patients with established and active RA.
引用
- Sauer BC, Chen W, Shen J, et al. Potential for Major Therapeutic Changes to Produce Significant Clinical Response Across a Broad Range of Disease Activity: An Observational Study of US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021. PMID: 32166882. doi:10.1002/acr.24183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。